First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.

ABSTRACT:

Unlabelled

Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in human prostate cancer and uPAR has been found to be associated with metastatic disease and poor prognosis. AE105 is a small linear peptide with high binding affinity to uPAR. We synthesized an N-terminal NOTA-conjugated version (NOTA-AE105) for development of the first (18)F-labeled uPAR positron-emission-tomography PET ligand using the Al(18)F radiolabeling method. In this study, the potential of (18)F-AlF-NOTA-AE105 to specifically target uPAR-positive prostate tumors was investigated.

Methods

NOTA-conjugated AE105 was synthesized and radiolabeled with (18)F-AlF according to a recently published optimized protocol. The labeled product was purified by reverse phase high performance liquid ch

SUBMITTER: Persson M 

PROVIDER: S-EPMC4217481 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature